237 related articles for article (PubMed ID: 33847204)
1. Clinical pharmacology of filgotinib in the treatment of rheumatoid arthritis: current insights.
Raimondo MG; Biggioggero M; Coletto LA; Ramming A; Caporali R; Favalli EG
Expert Rev Clin Pharmacol; 2021 Jun; 14(6):661-670. PubMed ID: 33847204
[TBL] [Abstract][Full Text] [Related]
2. Filgotinib, a novel JAK1-preferential inhibitor for the treatment of rheumatoid arthritis: An overview from clinical trials.
Tanaka Y; Kavanaugh A; Wicklund J; McInnes IB
Mod Rheumatol; 2022 Jan; 32(1):1-11. PubMed ID: 33740386
[TBL] [Abstract][Full Text] [Related]
3. Filgotinib for the treatment of rheumatoid arthritis.
Taylor PC; Abdul Azeez M; Kiriakidis S
Expert Opin Investig Drugs; 2017 Oct; 26(10):1181-1187. PubMed ID: 28838249
[TBL] [Abstract][Full Text] [Related]
4. Comparative efficacy and safety of 100 mg and 200 mg filgotinib administered to patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials
.
Song GG; Lee YH
Int J Clin Pharmacol Ther; 2020 Jun; 58(6):293-298. PubMed ID: 32301699
[TBL] [Abstract][Full Text] [Related]
5. Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial.
Genovese MC; Kalunian K; Gottenberg JE; Mozaffarian N; Bartok B; Matzkies F; Gao J; Guo Y; Tasset C; Sundy JS; de Vlam K; Walker D; Takeuchi T
JAMA; 2019 Jul; 322(4):315-325. PubMed ID: 31334793
[TBL] [Abstract][Full Text] [Related]
6. Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition.
Dowty ME; Lin TH; Jesson MI; Hegen M; Martin DA; Katkade V; Menon S; Telliez JB
Pharmacol Res Perspect; 2019 Dec; 7(6):e00537. PubMed ID: 31832202
[TBL] [Abstract][Full Text] [Related]
7. Current jakinibs for the treatment of rheumatoid arthritis: a systematic review.
Rocha CM; Alves AM; Bettanin BF; Majolo F; Gehringer M; Laufer S; Goettert MI
Inflammopharmacology; 2021 Jun; 29(3):595-615. PubMed ID: 34046798
[TBL] [Abstract][Full Text] [Related]
8. Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK-1 Inhibitor, After Short-Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials.
Vanhoutte F; Mazur M; Voloshyn O; Stanislavchuk M; Van der Aa A; Namour F; Galien R; Meuleners L; van 't Klooster G
Arthritis Rheumatol; 2017 Oct; 69(10):1949-1959. PubMed ID: 28622463
[TBL] [Abstract][Full Text] [Related]
9. Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2).
Kavanaugh A; Kremer J; Ponce L; Cseuz R; Reshetko OV; Stanislavchuk M; Greenwald M; Van der Aa A; Vanhoutte F; Tasset C; Harrison P
Ann Rheum Dis; 2017 Jun; 76(6):1009-1019. PubMed ID: 27993828
[TBL] [Abstract][Full Text] [Related]
10. Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1).
Westhovens R; Taylor PC; Alten R; Pavlova D; Enríquez-Sosa F; Mazur M; Greenwald M; Van der Aa A; Vanhoutte F; Tasset C; Harrison P
Ann Rheum Dis; 2017 Jun; 76(6):998-1008. PubMed ID: 27993829
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial.
Mease P; Coates LC; Helliwell PS; Stanislavchuk M; Rychlewska-Hanczewska A; Dudek A; Abi-Saab W; Tasset C; Meuleners L; Harrison P; Besuyen R; Van der Aa A; Mozaffarian N; Greer JM; Kunder R; Van den Bosch F; Gladman DD
Lancet; 2018 Dec; 392(10162):2367-2377. PubMed ID: 30360969
[TBL] [Abstract][Full Text] [Related]
12. JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib.
Traves PG; Murray B; Campigotto F; Galien R; Meng A; Di Paolo JA
Ann Rheum Dis; 2021 Jul; 80(7):865-875. PubMed ID: 33741556
[TBL] [Abstract][Full Text] [Related]
13. Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes.
Genovese M; Westhovens R; Meuleners L; Van der Aa A; Harrison P; Tasset C; Kavanaugh A
Arthritis Res Ther; 2018 Mar; 20(1):57. PubMed ID: 29566740
[TBL] [Abstract][Full Text] [Related]
14. Phase III trials of JAK1 selective inhibitors in rheumatoid arthritis.
Mysler E; Lizarraga A
Rheumatology (Oxford); 2021 May; 60(Suppl 2):ii17-ii23. PubMed ID: 33950225
[TBL] [Abstract][Full Text] [Related]
15. Filgotinib in rheumatoid arthritis.
Westhovens R
Expert Rev Clin Immunol; 2023 Feb; 19(2):135-144. PubMed ID: 36396615
[TBL] [Abstract][Full Text] [Related]
16. Exposure-response relationships for the efficacy and safety of filgotinib and its metabolite GS-829845 in subjects with rheumatoid arthritis based on phase 2 and phase 3 studies.
Meng A; Anderson K; Nelson C; Ni L; Chuang SM; Bellanti F; Chang P; Comisar C; Kearney BP; Bartok B; Mathias A
Br J Clin Pharmacol; 2022 Jul; 88(7):3211-3221. PubMed ID: 35072287
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection.
Namour F; Diderichsen PM; Cox E; Vayssière B; Van der Aa A; Tasset C; Van't Klooster G
Clin Pharmacokinet; 2015 Aug; 54(8):859-74. PubMed ID: 25681059
[TBL] [Abstract][Full Text] [Related]
18. Clinical Confirmation that the Selective JAK1 Inhibitor Filgotinib (GLPG0634) has a Low Liability for Drug-drug Interactions.
Namour F; Desrivot J; Van der Aa A; Harrison P; Tasset C; van't Klooster G
Drug Metab Lett; 2016; 10(1):38-48. PubMed ID: 26693854
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial.
van der Heijde D; Baraliakos X; Gensler LS; Maksymowych WP; Tseluyko V; Nadashkevich O; Abi-Saab W; Tasset C; Meuleners L; Besuyen R; Hendrikx T; Mozaffarian N; Liu K; Greer JM; Deodhar A; Landewé R
Lancet; 2018 Dec; 392(10162):2378-2387. PubMed ID: 30360970
[TBL] [Abstract][Full Text] [Related]
20. Early phase studies of JAK1 selective inhibitors in rheumatoid arthritis.
Avci AB; Feist E; Burmester GR
Rheumatology (Oxford); 2021 May; 60(Suppl 2):ii11-ii16. PubMed ID: 33950228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]